Chromocell Therapeutics Corp (CHRO)

Chromocell Therapeutics will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Cap n/a
Revenue (ttm) n/a
Net Income (ttm) -1.93M
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About CHRO

Chromocell Therapeutics Corp is a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the struc... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 3
Stock Exchange NASDAQ
Ticker Symbol CHRO
Full Company Profile

Financial Performance

Financial Statements


Chromocell Therapeutics Files for IPO

Chromocell Therapeutics Corp. filed for an initial public offering with the U.S. Securities and Exchange Commission on Wednesday.

2 weeks ago - MarketWatch

Chromocell Therapeutics IPO Registration Document (S-1)

Chromocell Therapeutics has filed to go public with an IPO on the Nasdaq.

2 weeks ago - SEC